Company intelligence / Profile preview

HLS Therapeutics Inc.

Toronto, Ontario, Canadahlstherapeutics.com ↗

Ownership: Public · HLS
Employees: ~92
Development stage: Commercial

Overview

HLS Therapeutics manages a portfolio of commercial stage branded medicines including CLOZARIL (clozapine) and VASCEPA (icosapent ethyl). In Q1 2024, product sales in Canada increased 3.5% compared to Q1 2023, led by growth in Vascepa sales. The company expects 2024 consolidated revenue in the range of $60-62 million and Adjusted EBITDA of $17-19 million.[2][10]

Therapeutic areas: PsychiatryCardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

clozapine

Commercial

Indications: Psychiatric disorders

1 more asset in the full pipeline.

Request access →

Partnerships

Pfizer Inc. (being terminated in 2024)Saladax Biomedical Inc.

Financials

Market cap: $45.7B
Total revenue: $11.2B
Enterprise value: $43.2B

Beyond the preview

Go deeper on HLS Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLS Therapeutics Inc..

Explore the full profile